Assessment of clinical outcomes in acute stroke trials.
نویسندگان
چکیده
BACKGROUND AND PURPOSE Adequate outcome assessment is crucial to randomized trials. We wished to assess the types of outcomes used in acute stroke trials and the appropriateness of these outcomes and their analyses. METHODS Acute stroke trials from the Cochrane Stroke Group's database were included from 1955 to 1995 if they were published in full text in English. For each trial we collected year of publication, number of patients randomized, blinding of outcome assessment, the specific outcome instruments used, the statistical methods used for analysis, and the significance of the results. The validity and reliability of each outcome measure were assessed by review of the literature. RESULTS Our study included 174 trials. Outcomes were assessed blindly in 69%. Death was recorded in only 76% of trials, impairment in 76%, disability in 42%, and handicap or quality of life in only 2%. Of the trials that measured impairment, 35% used a measure of established validity or reliability. For disability and handicap, the proportions with valid or reliable measures were 70% and 25%, respectively. Impairment and handicap measures were primarily analyzed as continuous variables, while disability was mainly analyzed as a dichotomous variable. Continuous data were usually analyzed with inappropriate parametric statistics. There was no relationship between the method of analysis, the type of outcome, and the statistical significance of results. CONCLUSIONS Most acute stroke trials up to 1995 have used clinical outcome measures that were inadequate in terms of their content, reliability, validity, blinded assessment, and statistical analysis. This has important implications for future stroke research.
منابع مشابه
Tenecteplase versus reteplase in acute myocardial infarction: A network meta-analysis of randomized clinical trials
Background: Acute myocardial infarction (AMI) is the leading cause of death throughout the world. One of the standard approaches to treatment of AMI is fibrinolysis. The study was conducted to evaluate the clinical efficacy of tenecteplase versus reteplase through network meta-analysis for AMI. Methods: Randomized trials were comprehensively searched in PubMed, Scopus, Cochrane library, a...
متن کاملTenecteplase versus reteplase in acute myocardial infarction: A network meta-analysis of randomized clinical trials
Background: Acute myocardial infarction (AMI) is the leading cause of death throughout the world. One of the standard approaches to treatment of AMI is fibrinolysis. The study was conducted to evaluate the clinical efficacy of tenecteplase versus reteplase through network meta-analysis for AMI. Methods: Randomized trials were comprehensively searched in PubMed, Scopus, Cochrane library, a...
متن کاملAcute Phase Reactants as a Prognostic Factor in Acute Stroke
Introduction: Elevated levels of CRP are present among patients at risk for further first-ever myocardial infarction and stroke. It has been shown that after ischemic stroke, increased levels of CRP are associated with unfavorable outcomes. Methods: From 120 patients admitted to the emergency unit of our hospital with the diagnosis of stroke CRP, D-dimer and ferritin level was measured and the ...
متن کاملClinical assessment of activities of daily living in acute stroke: Validation of the Persian version of Katz Index
Background: Katz Index is a well-known index for assessing basic activities of daily living. The aim was to determine validity and reliability of the Katz Index in Iranian patients with acute stroke. Methods: Eighty-seven patients (56 male, 31 female) with acute stroke (1-30 days post-stroke) participated in this psychometric properties study. Interval time for retest was 14 days. All partic...
متن کاملTrial Design and Reporting Standards for Intraarterial Cerebral Thrombolysis for Acute Ischemic Stroke The Technology Assessment Committees of the American Society of Interventional and Therapeutic Neuroradiology and the Society of Interventional Radiology
THE National Institutes of Health (NIH) estimates that stroke costs now exceed $45 billion per year. Stroke is the third leading cause of death, and one of the leading causes of adult disability, in North America, Europe, and Asia. A number of randomized stroke trials and case series have now been reported in the literature to evaluate the safety and efficacy of thrombolytic therapy for the tre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Stroke
دوره 29 5 شماره
صفحات -
تاریخ انتشار 1998